A cross-sectional analysis evaluated the impact of hope and optimism on different facets of psychological distress among patients with advanced melanoma, colorectal, lung, or gastrointestinal cancers.
Research into the potential of radiation therapy in the management of mesothelioma may improve the prognosis, and possibly extend progression-free survival, for patients with this incurable cancer.
Researchers in Montreal presented results of a study on the effects of using a pivot nurse in oncology (PNO) on continuity of care, outcomes, and quality of life for patients with lung cancer at the 2018 European Lung Cancer Congress.
Analysis of data from more than 1 million people demonstrates the value of tobacco-use data in tailoring public health programs to prevalence of smokers in local populations.
Researchers presented the preliminary results from an ongoing randomized, crossover study evaluating the cardiorespiratory effects of e-cigarettes.
Researchers conducted a case-control study that examined independent predictive factors of lung cancer in patients with chronic obstructive pulmonary disease.
The panel assembled and updated the above guidelines and recommendations regarding lung cancer screening and low-dose CT screening programs.
In a quasi-experimental pre-post study, researchers demonstrate the efficacy of the SEE-ACBT rehabilitation method on health-related and cost outcomes in patients with NSCLC who underwent curative lung resection.
Researchers assessed the efficacy of nabilone for improving symptoms of anorexia in patients with NSCLC. In addition, patient appetite, quality of life, and nutritional status were also assessed.
Excretion of metabolites of acrylonitrile, acrolein, propylene oxide, acrylamide, crotonaldehyde up
Study finds metals, including lead, leak from e-cigarette heating coils into inhaled aerosols
[Cancer Management and Research] The presence of comorbidities is thought to play a significant role in the decision to treat patients with NSCLC, and this impacts survival.
Using MVIC and 6MWT, researchers sought to determine if patients' exercise behaviors changed after a diagnosis of advanced lung cancer.
Researchers conducted a systematic literature search to identify studies investigating the effectiveness of preoperative exercise on outcomes among oncology patients undergoing surgery.
Efficacy and Safety of COX-2 Inhibitors for Advanced Non-small-cell Lung Cancer With Chemotherapy: A Meta-analysis
[OncoTargets and Therapy] This meta-analysis assesses the efficacy and safety profile of COX-2 inhibitors in patients with advanced non-small-cell lung cancer.
In a review of data from the NLST, researchers sought to determine if a risk-targeting approach would more efficiently select high-risk persons for lung cancer screening than the eligibility criteria defined by the NLST.
Platinum-based chemotherapy agents for lung cancer may increase the risk for thromboembolism.
Qualitative risk statements of malignancy for indeterminate pulmonary nodules are imprecise, highly variable, and should be replaced by a standard scale.
PSPT significantly reduced radiation exposure to the heart, but no differences were observed between PSPT and IMRT for the lung or esophagus.
Initial screens were least effective and least efficient for veterans with lowest lung cancer risk, according to this study.
Researchers found that nearly one third of veterans reported current use of a tobacco product, with cigarettes being most frequently used.
1. In terms of early lung cancer death per individual screened, targeting lung cancer mortality risk may improve lung cancer screening efficiency. 2. However, the increases in efficiency were attenuated when measured by life-years, quality-adjusted life-years (QALYs), and cost-effectiveness. Evidence Rating Level: 2 (Good) Study Rundown: Current guidelines for lung cancer screening using low-dose computed 
Osimertinib improves progression-free survival in EGFR-mutated non-small-cell lung cancer: The FLAURA trial
1. Osimertinib demonstrated a significantly longer duration of progression-free survival compared to standard of care epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKI) in patients with untreated EGFR-mutated locally-advanced or metastatic non-small-cell lung cancer (NSCLC). 2. Osimertinib treated patients had fewer grade 3 or higher adverse events compared to patients treated with standard EGFR-TKI therapy. 
Abstinence-contingent incentives improved smoking cessation outcomes among economically disadvantaged smokers with mental illness.
Abstinent smokers may have reduced preoperative pain tolerance and increased postoperative opioid use compared with nonsmokers.
Using data from the TUS-CPS, researchers sought to determine the effect of pharmaceutical smoking cessation aids on long-term quit rates among patients who smoke tobacco.
SBRT provides excellent local control and an adequate safety profile, but there is a lack of data comparing SBRT to resection among patients eligible for surgery.
Nab-paclitaxel/carboplatin Induction in Squamous NSCLC: Longitudinal Quality of Life While on Chemotherapy
[Lung Cancer: Targets and Therapy] Researchers examine the affect of first-line nab-paclitaxel plus carboplatinon QoL for patients with advanced non-small cell lung cancer.
Results of this randomized, phase 3 study comparing oral gefitinib with IV vinorelbine plus cisplatin revealed the effect of these regimens on disease-free survival in patients with exon 19 deletion or exon Leu585Arg NSCLC.
In lung cancer, it is critical to evaluate the resistance mechanisms so appropriate treatment can be administered.
Approval was based on results from ALEX, for which researchers randomly assigned 303 patients with ALK-positive NSCLC not previously treated with systemic therapy to receive alectinib or crizotinib.
Populating a microsimulation of model of HIV disease, researchers investigated the the likelihood of lung cancer-related morbidity and mortality among patients with HIV who smoke, based on smoking intensity.
A post-hoc analysis of 2 clinical trials was conducted to determine the safety and effectiveness of NEPA for managing CINV in patients with lung cancer who received platinum-based chemotherapy.
This study evaluated the feasibility and potential efficacy of a yoga intervention for patients with NSCLC and their caregivers.
Impact of language barrier and patient ethnicity on time interval from diagnosis to treatment for patients with NSCLC was measured at a public hospital and a private hospital.
In this case, a female patient with advanced lung cancer experiences a rare episode of nivolumab-induced Herzmyasthenie, emphasizing the need to be aware of the potential for rapid myocarditis concomitant with MG in patients undergoing treatment with anti-PD-1 monoclonal antibodies.
PanCan study results demonstrate the effectiveness of a novel predictive model in identifying risk of lung cancer in patients who do not meet the screening criteria of other models, including those used in the NLST.
Two phase 3 studies reveal the clinical benefit, safety profile, and overall survival of nivolumab and docetaxel for patients with squamous and nonsquamous NSCLC.
Osimertinib in the Treatment of Non-small Cell Lung Cancer: Design, Development and Place in Therapy
[Lung cancer: Targets and Therapy] This research examines clinical data from Phase I-III trials of osimertinib, discusses mechanisms of resistance to osimertinib, and provides an outlook for the use of osimertinib and novel therapeutic combinations to improve EGFR-mutated NSCLC outcomes.
Combining radiotherapy and immunotherapy has shown early promise against some advanced cancers, but oncology nurses need to be wary of potential overlapping toxicity profiles from each of these treatment modalities.
Researchers present findings of a phase 2 study that compared PFS when SBRT is administered prior to maintenance chemotherapy in patients with limited metastatic NSCLC vs chemotherapy alone. Data was presented at ASTRO 59th Annual Meeting.
This case demonstrates that, although rare, spontaneous TLS can occur even in the absence of chemotherapy, and a high index of suspicion for the effect should be maintained when patients with malignancies demonstrate the classic symptom of laboratory abnormalities.
Bevacizumab-awwb is a recombinant IgG1 monoclonal antibody that works by binding to vascular endothelial growth factor (VEGF) and inhibits angiogenesis.
Patients with stage III NSCLC have a poor median PFS of 8 months despite achieving a good response to the current standard of care of platinum-based double chemotherapy with concurrent radiotherapy.
Significant increases seen in heart rate and arterial stiffness were observed in the first 30 minutes after smoking electronic-cigarette containing nicotine.
Investigators report that administering cannabis to patients with cancer undergoing immunotherapy was found to lower the response rate to therapy but had no effect on PFS or OS, in an oral presentation at ESMO 2017 Congress.
An investigation into the challenges of lung cancer clinical trials found that despite a lack of participants being detrimental to successful trial completion, clinical trials are trending toward increasing their eligibility criteria, making it more difficult to accrue enough eligible participants.
Chronic obstructive pulmonary disease in patients with lung cancer: prevalence, impact and management challenges
[Lung Cancer: Targets and Therapy] Chronic obstructive pulmonary disease and lung cancer share a common etiological factor and usually coexist in everyday clinical practice.
Vitamin B intake appears to be related to lung cancer risk, but only for men or male smokers.
A retrospective analysis showed an association between depth of response (DepOR) and greater overall survival and longer progression-free survival.
[Lung Cancer: Targets and Therapy] This research reviews the current literature on psychosocial interventions in lung cancer, and discusses .
Data from 5 phase 2/3 studies demonstrate improved weight and body mass in patients with NSCLC receiving anamorelin.
A study on a cohort of women enrolled in the WHI-OS shows that those with a history of periodontal disease had a higher risk for developing some cancers.
Contrary to some concerns, persons at high risk for lung cancer who undergo CT lung scans are more likely to attempt smoking cessation regardless of their test results compared with unscreened persons.
A recent study demonstrated that eating a diet high in saturated fats and low in polyunsaturated fats may increase a person's risk of developing lung cancer.
The Lung Cancer Prognostic Index (LCPI) provides additional relevant prognostic data for patients with NSCL and may lead to better outcomes.
This fact sheet examines so-called "light" cigarettes, associated cancer risks, and tar yield ratings.
Acupuncture was found to improve cancer-related fatigue in patients with lung cancer in as little as 2 weeks, according to results of a double-blind randomized clinical study.
An analysis of rates at certain milestones in clinical trials of treatments for mNSCLC suggests these rates reflect end point results for immunotherapies vs targeted and conventional therapies.
E-cigarettes used with nicotine-based liquid have the same potential to produce cancer-causing DNA damage as unfiltered regular cigarettes.
Doses May Be Adjusted for Treating NSCLC Patients
Phase 3 clinical trial results show fewer adverse effects and longer survival with alectinib compared with crizotinib in patients with treatment-naïve ALK-positive NSCLC.
Developing a lung cancer screening program involves a number of challenges, including identifying patients in need of screening, patient follow-up, and community support.
Twice daily radiation therapy with chemotherapy may improve survival times in patients with some advanced head and neck cancers, a new study confirms.
The design of cigarette filters with ventilation is associated with rising adenocarcinoma rates, research indicates.
Study finds a correlation between various measures of neurocognitive function and health utility scores.
Counseling current smokers and helping to direct their care may reduce lung cancer mortality in underserved low-income populations.
A combination treatment of mitogen-activated protein kinase MEK inhibitor and chemotherapy did not improve progression-free survival in patients with advanced lung cancer caused by a KRAS gene mutation.
Seasonal influenza vaccination was associated with increased rates of immunologic toxicity in patients with lung cancer receiving PD-1/PD-L1 immunotherapy blockade.
A significantly higher 5-year survival rate was seen in a small subset of patients with NSCLC treated with nivolumab.
Regular infusions of high doses of vitamin C safely increased cancer cell sensitivity to treatment in patients with brain and lung cancers.
Checkpoint inhibitor pembrolizumab appears well-tolerated with antitumor activity in patients with malignant pleural mesothelioma.
Risk for cardiac events linked to RT for locally advanced NSCLC, especially in patients with a history of cardiac disease or receiving higher RT doses.
Prospective pilot study demonstrates accuracy of circulating tumor cells as a biomarker indicating lung cancer recurrence.
A free lung cancer screening program in Augusta, Georgia, found more than double the lung cancer rate of previous screenings.
Patients were more comfortable with their decisions about lung cancer screening after a shared decision-making visit.
Patients with metastatic kidney cancer may also have an primary lung cancer that has gone gone undiagnosed.
Novel diagnostic test determines whether suspicious lung lesions or nodules are malignant disease from a sample obtained via nasal swab.
A study of a large, diverse patient population appears to show an increasing incidence of lung cancer in patients who have never smoked tobacco.
Statins provide no benefits, or adverse effects, in patients with lung cancer, according to a phase 3 trial.
Treatment with radiation therapy for invasive breast cancer may place East Asian women at a greater risk of developing second primary lung cancer (SPLC).
A clinical pathways navigation program for patients with non-small cell lung cancer significantly reduced cost of care while preserving clinical outcomes.
The addition of pravastatin to first-line chemotherapy did not improve overall survival or progression-free survival in patients with small-cell lung cancer.
Ceritinib has been granted Priority Review as a first-line treatment for patients with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer.
E-cigarettes and replacement nicotine therapy deposit fewer harmful chemicals in the body that smoking.
Elderly with NSCLC have lower incidence of esophagitis, can tolerate aggressive radiation therapy.
Annual lung cancer screening of only high-risk smokers more cost-effective than current methods.
Researchers estimate that out of the 6.8 million current and former smokers eligible for lung cancer screening in 2015, only a fraction received it.
There are a growing number of NSCLC patients with advanced disease who are opting to forgo treatment despite the fact that receiving standard of care treatment leads to a higher OS.
A higher consumption of nuts was associated with a lower overall risk for developing lung cancer irrespective of smoking status.
Second study shows increase in lung cancer screening from 1.3 to 2.1 percent from 2010 to 2015
The addition of bevacizumab to first-line treatment with cisplatin plus etoposide improved PFS, but not OS, with an acceptable toxicity profile in patients with extensive-disease SCLC.
Treatment options for brain metastases in patients with EGFR-mutant NSCLC include SRS, WBRT, and EGFR TKIs. In this study, researchers sought to determine the optimal treatment approach of those who develop brain metastases and have not received EFGR TKIs.
Ceritinib is a kinase inhibitor indicated for the treatment of patients with ALK-positive metastatic NSCLC who have progressed on or are intolerant to crizotinib; in this study, researchers determined the efficacy of ceritinib in patients with untreated ALK-rearranged NSCLC.
Study found 21 percent of those with late-stage non-small cell lung cancer went without therapy, even though it could boost survival.
Annual counseling could reduce prevalence and prevent many smoking-attributable fatalities.
Analyses of lung tumor specimens were used to determine whether mutational profiles of lung cancers differ between black and white patients. Such differences could explain differences in prognosis and lead to reductions in outcomes disparities.
Lung Cancer Navigator, a mobile, customizable app from LUNGEVITY, helps patients with lung cancer better understand their disease, manage medications, track symptoms, and access support.
Investigators report on trends in treatment of advanced-stage NSCLC from 2000 to 2011, including impact on survival and total Medicare spending.
Study evaluated differences in survival with respect to the time interval between tumor resection and initiation of postoperative chemotherapy in patients with NSCLC.
Sign Up for Free e-newsletters
- Study Finds Association Between Folate Intake and Risk of Cutaneous Melanoma
- Qualitative Analysis of Myeloma Patients' Experience Following Hematopoietic Stem Cell Transplant
- Melanoma Outcomes Improved With Nivolumab Alone or Plus Ipilimumab
- Involved-Field Radiotherapy Plus Chemotherapy Prolonged PFS in Follicular Lymphoma
- Patient Fears of Placebo Use in Clinical Trials
- Implementing an Ambulatory Adherence Program May Improve Oral Anticancer Medications Compliance
- Exercise Habits Influence Mortality in Adult Survivors of Childhood Cancer
- Managing Dyspnea With Fentanyl in Patients With Cancer at End of Life
- CALM: A Depression Intervention for Cancer Patients at the End of Life
- High BMI Among Premenopausal Women May Improve Risk for Breast Cancer
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|